- Home
- KNSL vs MRNA Comparison
KNSL vs MRNA Comparison
Compare KNSL & MRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KNSL
- MRNA
- Stock Information
- Founded
- KNSL 2009
- MRNA 2010
- Country
- KNSL United States
- MRNA United States
- Employees
- KNSL N/A
- MRNA N/A
- Industry
- KNSL Property-Casualty Insurers
- MRNA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- KNSL Finance
- MRNA Health Care
- Exchange
- KNSL Nasdaq
- MRNA Nasdaq
- Market Cap
- KNSL 10.9B
- MRNA 9.8B
- IPO Year
- KNSL 2016
- MRNA 2018
- Fundamental
- Price
- KNSL $389.13
- MRNA $23.75
- Analyst Decision
- KNSL Buy
- MRNA Hold
- Analyst Count
- KNSL 9
- MRNA 15
- Target Price
- KNSL $494.88
- MRNA $37.15
- AVG Volume (30 Days)
- KNSL 289.8K
- MRNA 11.3M
- Earning Date
- KNSL 10-23-2025
- MRNA 11-06-2025
- Dividend Yield
- KNSL 0.17%
- MRNA N/A
- EPS Growth
- KNSL 16.09
- MRNA N/A
- EPS
- KNSL 20.35
- MRNA N/A
- Revenue
- KNSL $1,802,839,000.00
- MRNA $3,078,000,000.00
- Revenue This Year
- KNSL $19.18
- MRNA N/A
- Revenue Next Year
- KNSL $8.03
- MRNA $11.12
- P/E Ratio
- KNSL $19.10
- MRNA N/A
- Revenue Growth
- KNSL 18.10
- MRNA N/A
- 52 Week Low
- KNSL $382.90
- MRNA $23.15
- 52 Week High
- KNSL $531.79
- MRNA $56.70
- Technical
- Relative Strength Index (RSI)
- KNSL 32.49
- MRNA 40.27
- Support Level
- KNSL $382.90
- MRNA $24.25
- Resistance Level
- KNSL $435.40
- MRNA $29.20
- Average True Range (ATR)
- KNSL 15.52
- MRNA 1.51
- MACD
- KNSL -7.05
- MRNA -0.28
- Stochastic Oscillator
- KNSL 7.77
- MRNA 0.64
About KNSL Kinsale Capital Group Inc.
Kinsale Capital Group Inc is an insurance holding company. The company is engaged in offering property, casualty, and specialty insurance products. It offers specialty insurance products for allied health, healthcare, life sciences, professional, and a public entity. The company operates in only one reportable segment which is the Excess and Surplus Lines Insurance segment, which includes commercial excess and surplus lines liability and property insurance products through its underwriting divisions. The company generates revenues in the form of premiums and investment income.
About MRNA Moderna Inc.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.